1、Gall EA, Mallory TB. Malignant lymphoma: a clinico-pathologic survey of 618 cases[J]. Am J Pathol, 1942, 18(3): 381-429.
2、Stansbury FC. Lymphosarcoma of the eyelid, report of case, with death in 40 days[J]. Arch Ophthal, 1948, 39(5): 518-530.
3、Cooper EL, Riker JL. Malignant lymphoma of the uveal tract[J]. Am J Ophthalmol, 1951, 34(8): 1153-1158.
4、Vogel MH, Font RL, Zimmerman LE, et al. Reticulum cell sarcoma of the retina and uvea. Report of six cases and review of the literature[J]. Am J Ophthalmol, 1968, 66(2): 205-215.
5、Merle-Béral H, Davi F, Cassoux N, et al. Biological diagnosis of primary intraocular lymphoma[J]. Br J Haematol, 2004, 124(4): 469-473.
6、Coupland SE, Anastassiou G, Bornfeld N, et al. Primary intraocular lymphoma of T-cell type: report of a case and review of the literature[J]. Graefes Arch Clin Exp Ophthalmol, 2005, 243(3): 189-197.
7、Wallace DJ, Altemare CR, Shen DF, et al. Primary testicular and intraocular lymphomas: two case reports and a review of the literature[J]. Surv Ophthalmol, 2006, 51(1): 41-50.
8、Vosganian GS, Boisot S, Hartmann KI, et al. Primary intraocular lymphoma: a review[J]. J Neurooncol, 2011, 105(2): 127-134.
9、Coupland SE, Dodson A, Liu H, et al. Intraocular collision tumour: case report and literature review[J]. Graefes Arch Clin Exp Ophthalmol, 2013, 251(5): 1383-1388.
10、Merle H, Hage R, Meniane JC, et al. Retinal manifestations in adult T-cell leukemia/lymphoma related to infection by the human T-cell lymphotropic virus type- 1[J]. Retina, 2016, 36(7): 1364-1371.
11、Char DH, Ljung BM, Miller T, et al. Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management[J]. Ophthalmology, 1988, 95(5): 625-630.
12、Coupland SE, Chan CC, Smith J. Pathophysiology of retinal lymphoma[J]. Ocul Immunol Inffamm, 2009, 17(4): 227-237.
13、Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma[J]. Discov Med 2013, 15(84): 93-100
14、Rappaport H. Tumors of the Hematopoietic System. Atlas of Tumor Pathology[M]. Washington, DC., USA: Armed Forces Institute of Pathology, 1966.
15、Harris NL, Jaffe ES, Stein H, et al. A revised European- American classiffcation of lymphoid neoplasms: a proposal from the International Lymphoma Study Group[J]. Blood, 1994, 84(5): 1361-1392.
16、WHO. WHO classiffcation of tumours of haematopoietic and lymphoid tissues[J]. 4th ed. Lyon: IARC Press, 2008.
17、Campo E, Swerdlow SH, Harris NL, et al. TTe 2008 WHO classiffcation of lymphoid neoplasms and beyond: evolving concepts and practical applications[J]. Blood, 2011, 117(19): 5019-5032.
18、Swerdlow SH, Campo E, Pileri SA, et al. TTe 2016 revision of the World Health Organization classiffcation of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390.
19、Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling[J]. Nature, 2000, 403(6769): 503-511.
20、Dunleavy K, Wilson WH. Appropriate management of molecular subtypes of diffuse large B-cell lymphoma[J]. Oncology (Williston Park), 2014, 28(4): 326-334.
21、Young RM, Shaffer AL, 3rd, Phelan JD, et al. B-cell receptor signaling in diffuse large B-cell lymphoma[J]. Semin Hematol, 2015, 52(2): 77-85.
22、Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era[J]. Nat Rev Clin Oncol, 2014, 11(1): 12-23.
23、Cao X, Shen D, Callanan DG, et al. Diagnosis of systemic metastatic retinal lymphoma[J]. Acta Ophthalmol, 2011, 89(2):e149-54.
24、Fonkem E, Lok E, Robison D, et al. TTe natural history of intravascular lymphomatosis[J]. Cancer Med, 2014, 3(4): 1010-1024.
25、Salom%C3%A3o%20DR%2C%20Pulido%20JS%2C%20Johnston%20PB%2C%20et%20al.%20Vitreoretinal%20presentation%20of%20secondary%20large%20B-cell%20lymphoma%20in%20patients%20with%20systemic%20lymphoma%5BJ%5D.%20JAMA%20Ophthalmol%2C%202013%2C%20131(9)%3A%201151-1158.%20
26、Davis JL. Intraocular lymphoma: a clinical perspective. Eye (Lond) 2013, 27(2): 153-162.
27、Chan CC, Gonzales JA. Primary intraocular lymphoma[M]. World Scientiffc Publishing Co. Pte. Ltd., 2007.
28、Cochereau I, Hannouche D, Geoffray C, et al. Ocular involvement in Epstein-Barr virus-associated T-cell lymphoma[J]. Am J Ophthalmol, 1996, 121(3): 322-324.
29、Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma[J]. Retina, 2011, 31(3): 435-440.
30、Velez G, Chan CC, Csaky KG. Fluorescein angiographic findings in primary intraocular lymphoma[J]. Retina, 2002, 22(1): 37-43
31、Whitcup SM, de Smet MD, Rubin BI, et al. Intraocular lymphoma. Clinical and histopathologic diagnosis[J]. Ophthalmology, 1993, 100(9): 1399-1406.
32、Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium[J]. Oncologist, 2011, 16(11): 1589-1599.
33、Fardeau C, Lee CP, Merle-Beral H, et al. Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma[J]. Am J Ophthalmol, 2009, 147(5): 886-894.
34、Keino H, Okada AA, Watanabe T, et al. Spectral-domain Optical Coherence Tomography Patterns in Intraocular Lymphoma. Ocul Immunol Inffamm, 2016, 24(3): 268-273.
35、White VA, Gascoyne RD, Paton KE. Use of the polymerase chain reaction to detect B- and T-cell gene rearrangements in vitreous specimens from patients with intraocular lymphoma[J]. Arch Ophthalmol, 1999, 117(6): 761-765.
36、Davis JL, Solomon D, Nussenblatt RB, et al. Immunocytochemical staining of vitreous cells. Indications, techniques, and results[J]. Ophthalmology, 1992, 99(2): 250-256.
37、Raparia K, Chang CC, Chevez-Barrios P. Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens[J]. Arch Pathol Lab Med, 2009, 133(8): 1233-1237.
38、Sharara N, Holden JT, Wojno TH, et al. Ocular adnexal lymphoid proliferations: clinical, histologic, ffow cytometric, and molecular analysis of forty-three cases[J]. Ophthalmology, 2003, 110(6): 1245-1254.
39、French DL, Laskov R, Scharff MD. TTe role of somatic hypermutation in the generation of antibody diversity[J]. Science, 1989, 244(4909): 1152-1157.
40、Chan CC. Molecular pathology of primary intraocular lymphoma[J]. Trans Am Ophthalmol Soc, 2003, 101: 275-92.
41、Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma[J]. Curr Opin Ophthalmol, 2002, 13(6): 411-418.
42、Diaz-Cano S. PCR-based alternative for diagnosis of immunoglobulin heavy chain gene rearrangement: principles, practice, and polemics[J]. Diagn Mol Pathol, 1996, 5(1): 3-9.
43、Levy-Clarke GA, Chan CC, Nussenblatt RB. Diagnosis and management of primary intraocular lymphoma[J]. Hematol Oncol Clin North Am, 2005, 19(4): 739-749.
44、Shen DF, Zhuang Z, LeHoang P, et al. Utility of microdissection and polymerase chain reaction for the detection of immunoglobulin gene rearrangement and translocation in primary intraocular lymphoma[J]. Ophthalmology, 1998, 105(9): 1664-1669.
45、Chan CC, Shen D, Nussenblatt RB, et al. Detection of molecular changes in primary intraocular lymphoma by microdissection and polymerase chain reaction[J]. Diagn Mol Pathol, 1998, 7(1): 63-64.
46、Murray PI, Hoekzema R, van Haren MA, et al. Aqueous humor interleukin-6 levels in uveitis[J]. Invest Ophthalmol Vis Sci, 1990, 31(5): 917-920.
47、Chan CC, Whitcup SM, Solomon D, et al. Interleukin-10 in the vitreous of patients with primary intraocular lymphoma[J]. Am J Ophthalmol, 1995, 120(5): 671-673.
48、Whitcup SM, Stark-Vancs V, Wittes RE, et al. Association of interleukin 10 in the vitreous and cerebrospinal ffuid and primary central nervous system lymphoma[J]. Arch Ophthalmol, 1997, 115(9): 1157-1160.
49、Wolf LA, Reed GF, Buggage RR, et al. Vitreous cytokine levels[J]. Ophthalmology, 2003, 110(8): 1671-1672.
50、Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma[J]. Invest Ophthalmol Vis Sci, 2007, 48(7): 3253-3259.
51、Sugita S, Takase H, Sugamoto Y, et al. Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine proffling of the vitreous ffuid[J]. Jpn J Ophthalmol, 2009, 53(3): 209-214.
52、Fisson S, Ouakrim H, Touitou V, et al. Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis[J]. PLoS One, 2013, 8(2): e52385.
53、Ramkumar HL, Shen DF, Tuo J, et al. IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas[J]. Graefes Arch Clin Exp Ophthalmol, 2012, 250(10): 1541-1548.
54、Tuo J, Shen D, Yang HH, et al. Distinct microRNA-155 expression in the vitreous of patients with primary vitreoretinal lymphoma and uveitis[J]. Am J Ophthalmol, 2014, 157(3): 728-734.
55、Wang Y, Shen D, Wang VM, et al. Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma[J]. Int J Mol Sci, 2011, 12(9): 5684-5697.
56、Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and management[J]. Cancer Control, 2004, 11(5): 285-295.
57、Nussenblatt RB, Chan CC, Wilson WH, et al. International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future[J]. Ocul Immunol Inffamm, 2006, 14(3): 139-144.
58、Pe'er J, Hochberg FH, Foster CS. Clinical review: treatment of vitreoretinal lymphoma[J]. Ocul Immunol Inffamm, 2009, 17(5): 299-306.
59、Hormigo A, Abrey L, Heinemann MH, et al. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment[J]. Br J Haematol, 2004, 126(2): 202-208.
60、Isobe K, Ejima Y, Tokumaru S, et al. Treatment of primary intraocular lymphoma with radiation therapy: a multi-institutional survey in Japan[J]. Leuk Lymphoma, 2006, 47(9): 1800-1805
61、Teckie S, Yahalom J. Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone[J]. Leuk Lymphoma, 2014, 55(4): 795-801.
62、de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma[J]. Br J Ophthalmol, 1999, 83(4): 448-451.
63、Taoka K, Yamamoto G, Kaburaki T, et al. Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy[J]. Br J Haematol, 2012, 157(2): 252-254.
64、Raja H, Snyder MR, Johnston PB, et al. Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma[J]. PLoS One, 2013, 8(6): e65627.
65、Wang JK, Yang CM, Lin CP, et al. An Asian patient with intraocular lymphoma treated by intravitreal methotrexate[J]. Jpn J Ophthalmol, 2006, 50(5): 474-478.
66、Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience[J]. Br J Ophthalmol, 2008, 92(3): 383-388.
67、Ghasemi Falavarjani K, Golabi S, Hadavandkhani A. Effect of intravitreal injection of methotrexate on human corneal endothelial cells[J]. Cornea, 2016, 35(2): 217-219.
68、Sen HN, Chan CC, Byrnes G, et al. Intravitreal methotrexate resistance in a patient with primary intraocular lymphoma[J]. Ocul Immunol Inffamm, 2008, 16(1): 29-33.
69、Venkatesh P, Gogia V, Khanduja S, et al. Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy[J]. J Cancer Res TTer, 2015, 11(3): 668.
70、Akiyama H, Takase H, Kubo F, et al. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma[J]. Cancer Sci, 2016, 107(10): 1458-1464.
71、Ma WL, Hou HA, Hsu YJ, et al. Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic highdose methotrexate and intravitreal methotrexate injection[J]. Ann Hematol, 2016, 95(4): 593-601.
72、Li H, Zhang G, Jiang C, et al. Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster[J]. Oncotarget, 2015, 6(27): 24192-24204.
73、Jaeger U, Trneny M, Melzer H, et al. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial[J]. Haematologica, 2015, 100(7): 955-963.
74、Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma[J]. J Clin Oncol, 1997, 15(10): 3266-3274
75、Kitzmann AS, Pulido JS, Mohney BG, et al. Intraocular use of rituximab[J]. Eye (Lond) , 2007, 21(12): 1524-1527.
76、Hashida N, Ohguro N, Nishida K. Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma[J]. Transl Vis Sci Technol 2012, 1(3): 1.
77、Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis[J]. Nat Clin Pract Rheumatol, 2007, 3(2): 86-95
78、Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma[J]. Neurology, 2014, 83(3): 235-239.
79、Itty S, Olson JH, O'Connell DJ, et al. Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy[J]. Retina, 2009, 29(3): 415-416.
80、Yeh S, Wilson DJ. Combination intravitreal rituximab and methotrexate for massive subretinal lymphoma[J]. Eye (Lond) , 2010, 24(10): 1625-1627.
81、Larkin KL, Saboo US, Comer GM, et al. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma[J]. Br J Ophthalmol, 2014, 98(1): 99-103.
82、Riemens A, Bromberg J, Touitou V, et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study[J]. JAMA Ophthalmol, 2015, 133(2): 191-197.
83、Hashida N, Nakai K, Saitoh N, et al. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma[J]. Graefes Arch Clin Exp Ophthalmol, 2014, 252(4): 687-693.
84、Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma[J]. Nature, 2010, 463(7277): 88-92.
85、Wu J, Liu C, Tsui ST, et al. Second-generation inhibitors of Bruton tyrosine kinase[J]. J Hematol Oncol, 2016, 9(1): 80.
86、Ponader S, Burger JA. Bruton's tyrosine kinase: from X-linked agammaglobulinemi a toward targeted therapy for B- cell malignancies[J]. J Clin Oncol, 2014, 32(17): 1830-1839.
87、de Rooij MF, Kuil A, Kraan W, et al. Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4- controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia[J]. Haematologica, 2016, 101(3): e111-e115.
88、Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has signiffcant activity in patients with relapsed/refractory B-cell malignancies[J]. J Clin Oncol, 2013, 31(1): 88-94.
89、Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma[J]. Nat Med, 2015, 21(8): 922-926.
90、Bonzheim I, Giese S, Deuter C, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates[J]. Blood, 2015, 126(1): 76-79.
91、Rubenstein JL, Gupta NK, Mannis GN, et al. How I treat CNS lymphomas[J]. Blood, 2013, 122(14): 2318-2330.
92、Schorb E, Finke J, Ferreri AJ, et al. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix)[J]. BMC Cancer, 2016, 16: 282
93、Cho H, Chang JH, Kim YR, et al. TTe role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma[J]. Br J Haematol, 2016, 174(3): 444-453.
94、Kamio T, Yokohama A, Hayashi T, et al. Relapsed primary intraocular lymphoma treated with intravitreal methotrexate and high-dose chemotherapy followed by autologous stem cell rescue[J]. Rinsho Ketsueki, 2014, 55(2): 244-248.
95、Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network[J]. Neuro Oncol, 2016, 18(9): 1297-1303.
96、Kreher S, Strehlow F, Martus P, et al. Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial[J]. Ann Hematol, 2015, 94(3): 409-414.
97、Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report[J]. Neurology, 2008, 71(17): 1355-1360.